Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) and increased its price target from $75 to$90. The firm attributed the higher target to favorable financial forecasts and solid earnings results for the first half of 2025. Benchmark’s revised price target depends on the biotechnology company’s projected 2025 revenues being 8.5 times higher. The firm also reported that Mer ...